Gilead Sciences (GILD) said Friday that its experimental drug, trodelvy, met the primary endpoint in a phase 3 trial, showing a statistically significant and clinically meaningful improvement in progression-free survival over chemotherapy in patients with a type of breast cancer who are not candidates for immunotherapy.
The company said the drug's safety profile in the study was consistent with previous trials, with no new safety signals observed.
The drugmaker said overall survival, a key secondary endpoint, was not yet mature at the time of analysis, and further monitoring is underway.
Gilead said it is also evaluating trodelvy in multiple ongoing phase 3 studies across various tumor types, including HER2-negative breast cancer, lung, and gynecologic cancers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.